市場調査レポート

商品コード

1588505

爪真菌症治療の市場規模、シェア、成長分析、治療タイプ別、適応疾患別、年齢層別、性別、流通チャネル別、地域別 - 産業予測、2024年～2031年

Onychomycosis Treatment Market Size, Share, Growth Analysis, By Treatment Type, By Disease Indication, By Age Group, By Gender, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年11月04日
発行: SkyQuest
ページ情報: 英文 208 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の爪真菌症治療の市場規模は、2022年に45億2,000万米ドルとなり、2023年の49億1,000万米ドルから、2031年までには95億米ドルに成長し、予測期間（2024年～2031年）のCAGRは8.60％で成長する見通しです。

爪真菌症治療市場は、爪真菌症の有病率の増加、治療オプションの進歩、この疾患に対する意識の高まりによって大きな成長を遂げています。この市場には、外用薬、レーザー治療、経口抗真菌薬など、さまざまな治療法が含まれます。さらに、ヘルスケア支出の増加により、優れた治療法へのアクセスが向上しており、市場の拡大に拍車をかけています。しかし、高額な治療費や特定の治療に伴う潜在的な副作用などの課題が、市場の勢いを抑制しています。特にレーザー治療やイトラコナゾール、テルビナフィンなどの経口抗真菌薬などの先進治療は、経済的な障壁が患者の取り込みを阻害する可能性があります。さらに、これらの薬剤に関連する肝障害や胃腸合併症の可能性に対する懸念が、患者の消極的な姿勢を助長している可能性もあります。こうした課題にもかかわらず、ナノテクノロジーを駆使した製品や、徐放性製剤や効能の高い外用治療薬などのドラッグデリバリー・システムの強化など、医薬品開発の革新から生まれる機会によって、市場は成長する態勢を整えています。このような技術革新の出現により、患者の予後が改善され、ヘルスケアにおける爪水虫治療の魅力が高まることが期待されます。全体として、需要の高まりと治療オプションの進化が相互に作用して、爪真菌症治療市場のダイナミックな将来が示唆されています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主要な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Teva Pharmaceutical Industries Ltd.（Israel）
Sanofi S.A.（France）
Medimetriks Pharmaceuticals, Inc.（US）
Galderma（Switzerland）
Johnson & Johnson（US）
Novartis AG（Switzerland）
Moberg Pharma AB（Sweden）
Cardinal Health, Inc.（US）
Pfizer Inc.（US）
Almirall, S.A.（Spain）
Bayer AG（Germany）
Viatris Inc.（US）
GlaxoSmithKline plc（UK）
Cipla Ltd.（India）
Dr. Reddy's Laboratories Ltd.（India）
Evofem Biosciences, Inc.（US）
Nabriva Therapeutics plc（Ireland）
Kaken Pharmaceutical Co., Ltd.（Japan）
Hikma Pharmaceuticals PLC（UK）
Dermavant Sciences, Inc.（US）
Sientra, Inc.（US）
Zynerba Pharmaceuticals, Inc.（US）

Product Code: SQMIG35H2265

Global Onychomycosis Treatment Market size was valued at USD 4.52 billion in 2022 and is poised to grow from USD 4.91 billion in 2023 to USD 9.5 billion by 2031, growing at a CAGR of 8.60% during the forecast period (2024-2031).

The onychomycosis treatment market is witnessing significant growth driven by the increasing prevalence of nail fungal infections, advancements in treatment options, and heightened awareness about the condition. This market encompasses a variety of treatments, including topical solutions, laser therapies, and oral antifungal medications. Additionally, the rise in healthcare expenditure is enhancing accessibility to superior treatment alternatives, further fueling market expansion. However, challenges such as high treatment costs and potential side effects associated with certain therapies are constraining market momentum. Advanced treatments, particularly laser therapies and oral antifungals like itraconazole and terbinafine, may present financial barriers that deter patient uptake. Moreover, concerns over possible liver damage and gastrointestinal complications associated with these medications can contribute to patient reluctance. Despite these challenges, the market is poised for growth, bolstered by opportunities arising from innovations in drug development, including nanotechnology-driven products and enhanced drug delivery systems such as sustained-release formulations and highly efficacious topical treatments. As these innovations emerge, they hold the promise of improving patient outcomes and increasing the attractiveness of onychomycosis treatments in the healthcare landscape. Overall, the interplay of escalating demand and evolving therapeutic options suggests a dynamic future for the onychomycosis treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Treatment Market Segmental Analysis

Global Onychomycosis Treatment Market is segmented by Treatment Type, Disease Indication, Age Group, Gender, Distribution Channel, and region. Based on Treatment Type, the market is segmented into Drugs, Lasers, and Photodynamic Therapy. Based on Disease Indication, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis, and Total Dystrophic Onychomycosis. Based on Age Group, the market is segmented into 0 to 18 Years, 19 to 39 Years, 40 to 64 Years, and 65 Years & Above. Based on Gender, the market is segmented into Male, and Female. Based on Distribution Channel, the market is segmented into Institutional Sales, and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Onychomycosis Treatment Market

The Global Onychomycosis Treatment market is significantly driven by the increasing prevalence of fungal nail infections, largely attributed to an aging population, rising diabetes rates, and a higher incidence of immunocompromising conditions. As individuals age and comorbidities rise, the susceptibility to onychomycosis escalates, demanding effective treatment options. Additionally, heightened awareness among patients about fungal infections, coupled with improved diagnostic techniques and advanced treatment options being recognized by healthcare professionals, is leading to more accurate diagnoses and subsequent treatments. This confluence of factors not only curtails the stigma associated with fungal infections but also propels market growth as demand for effective therapies surges.

Restraints in the Global Onychomycosis Treatment Market

One prominent market restraint for the Global Onychomycosis Treatment market is the variability in treatment efficacy across diverse patient populations and infection profiles. Many available therapies may not deliver consistent results for all individuals, leading to a significant rate of recurrence, which can diminish patient trust and compliance. Furthermore, treatment effectiveness often hinges on the specific type and severity of the fungal infection, underscoring the imperative for ongoing research and development. This necessity for tailored solutions can hinder market growth, as healthcare providers grapple with the challenge of offering universally effective and reliable treatment options for onychomycosis.

Market Trends of the Global Onychomycosis Treatment Market

The global onychomycosis treatment market is witnessing a significant trend towards the adoption of advanced laser therapies, particularly Carbon Dioxide (CO2) and Blue Light lasers. CO2 lasers dominate this segment due to their ability to penetrate deeper into the nail bed, effectively targeting and eradicating stubborn fungal infections. Meanwhile, Blue Light therapies are gaining traction for treating mild cases or as adjunctive treatments, enhancing overall efficacy. With both modalities delivering heat energy to eliminate pathogens, the trend indicates a shift towards non-invasive, effective solutions, appealing to consumers seeking quick recovery with minimal side effects, thereby driving market growth and innovation.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
PESTEL Analysis
Top Investment Analysis
Key Success Factor
Degree of Competition

Onychomycosis Treatment Market by Treatment Type

Market Overview
Drugs
- Oral
- RX
- OTC
- Tropical
- RX
- OTC
Lasers
- C02 Ablative Lasers
- Nd: YAG Lasers
- Dual-wavelength near-infrared Lasers
Photodynamic Therapy

Onychomycosis Treatment Market by Disease Indication

Market Overview
Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Candidal Onychomycosis
Total Dystrophic Onychomycosis

Onychomycosis Treatment Market by Age Group

Market Overview
0 to 18 Years
19 to 39 Years
40 to 64 Years
65 Years & Above

Onychomycosis Treatment Market by Gender

Market Overview
Male
Female

Onychomycosis Treatment Market by Distribution Channel

Market Overview
Institutional Sales
- Hospitals
- Dermatology Clinics
Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies & Online Sales

Onychomycosis Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medimetriks Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galderma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moberg Pharma AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almirall, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evofem Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nabriva Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kaken Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dermavant Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sientra, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zynerba Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

爪真菌症治療の市場規模、シェア、成長分析、治療タイプ別、適応疾患別、年齢層別、性別、流通チャネル別、地域別 - 産業予測、2024年～2031年

Onychomycosis Treatment Market Size, Share, Growth Analysis, By Treatment Type, By Disease Indication, By Age Group, By Gender, By Distribution Channel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主要な市場の考察

爪真菌症治療市場：治療タイプ別

爪真菌症治療市場：適応疾患別

爪真菌症治療市場：年齢層別

爪真菌症治療市場：性別

爪真菌症治療市場：流通チャネル別

爪真菌症治療市場：地域別